e-Health

Between January 1 and June 1, 2026, seven MedTech-related mini-HTAs were initiated in Norway across orthopedics, neurology and rehabilitation, in vitro diagnostics, interventional radiology, diagnostic imaging, and e-health. These assessments are conducted as part of Norway’s framework for the managed introduction of innovations, known as “New Methods”.

On May 22, 2026, the Innovation Committee of the Federal Joint Committee (G-BA) published the decisions recommending the transfer of several other completed projects on new forms of care and healthcare research to standard care.

In May 2026, the National Institute for Health and Care Excellence (NICE) published two new Early Use HealthTech Guidances (HTGs) on digital technologies to support self-management of asthma and artificial intelligence (AI)-assisted technologies for echocardiography analysis and reporting in heart failure.

The Agency for Health Technology Assessment and Tariff System (AOTMiT) initiated seventeen new health technology assessments in Poland in the second quarter of 2026. The assessments mainly cover cardiovascular medicine, diagnostic imaging, e-health, in-vitro diagnostics, pulmonology, and neurology.

On May 20, 2026, the French Ministry of Health published the Decree, establishing a phase-out mechanism for older medical telemonitoring activities reimbursed via LATM when a newer, superior solution is registered for the same indication. Older solutions are subject to a 36-month transitional period before the removal, with three successive annual tariff reductions of 10% vs. the tariff of the newly registered solution.

In April 2026, the Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) updated the Digi-HTA assessment scale. Products are now scored across five evaluation subareas using a scale of 2, 1.7, 0.9, or -4. FinCCHTA issues its final recommendation through a traffic light model based on the total score, with 10 points corresponding to the green category and a score of 4 or below corresponding to the red category.

In April 2026, two HTA agencies working under the Spanish Network of HTA Agencies (RedETS) released several New and Emerging Health Technology Fact Sheets in cardiovascular, dermatology, diagnostic imaging, e-health, in-vitro diagnostics, men’s health, obstetrics and gynecology, peripheral vascular, robotic surgery and some other fields. The purpose of the Fact Sheets is to inform the prioritization of new and emerging technologies for evaluation by RedETS.

In April 2026, the National Institute for Health and Care Excellence (NICE) published two new HealthTech Guidances (HTGs) on transvenous embolization for spontaneous intracranial hypotension caused by a cerebrospinal fluid (CSF) venous fistula and digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centers. In addition, four clinical guidelines were updated.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the April 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favorable opinions were issued for the add-on reimbursement of 14 new devices and for the extension of indications for three devices. Opinions concerned multiple fields, including cardiovascular, diagnostic imaging, ENT, e-health, endocrine, interventional radiology, nephrology, neuromodulation, orthopedics, spine, peripheral vascular, and pulmonology.

In March-April 2026, Health Technology Wales (HTW) accomplished two full appraisals on salvage high-dose-rate brachytherapy for prostate cancer and AI-assisted ultrasound for the detection of deep vein thrombosis. Additionally, two Med Tech-related Topic Exploration Reports were published in the E-health and Pulmonology fields.

On April 16, 2026, the French Ministry of Health announced the inclusion of the first in vitro diagnostic medical device under the reformed RIHN 2.0, designed to support innovative diagnostics through temporary reimbursement while evidence is generated. The selected technology is VisioCyt Bladder, an AI-assisted digital urine cytology, indicated for monitoring recurrence in non-muscle-invasive bladder cancer. This marks a key milestone in the implementation of the updated framework.

On April 9, 2026, the Spanish Network of HTA Agencies (RedETS) published the 2026 working plan for health technology assessments. The plan includes a wide range of topics in cardiovascular, dermatology, diagnostic imaging, e-health, endocrine, endoscopy, gastrointestinal, ICU/OR, in-vitro diagnostics, neurology and neurosurgery, neuromodulation, ophthalmology, radiology, robotic surgery, and some other fields.